Physician profile
Deepa Aravind
NPI 1669677332
$4,140.32
in general payments reported to CMS, 2019-2025
34 companies · $1,584 in 2025
The $1,584 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.91 · 2020: $153 · 2021: $38.66 · 2022: $462 · 2023: $813 · 2024: $1,052 · 2025: $1,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,449.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $749.36 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $441.81 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $349.21 | 2023-2025 | Unithroid |
| Lilly USA, LLC | $324.56 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Dexcom, INC. | $298.43 | 2020-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $253.51 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Tandem Diabetes Care, INC. | $219.15 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $209.42 | 2022-2025 | Minimed 780g |
| Amgen INC. | $195.52 | 2022-2025 | Evenity, Prolia, Tepezza |
| Beta Bionics, INC. | $130.87 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sanofi-Aventis U.S. LLC | $98.88 | 2023-2025 | |
| Insulet Corporation | $84.09 | 2023-2025 | Omnipod |
| Radius Health, INC. | $78.06 | 2024-2025 | Tymlos |
| Nevro Corp. | $62.86 | 2024 | Senza |
| Baxter Healthcare | $58.71 | 2023 | Hillrom - Life 2000 Ventilation System |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rgh Enterprises LLC | $56.79 | 2025 | |
| Corcept Therapeutics | $53.81 | 2024 | Korlym |
| Ascensia Diabetes Care US INC. | $48.31 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $45.14 | 2022 | |
| Abbvie INC. | $40.94 | 2024-2025 | |
| Verity Pharmaceuticals INC. | $38.90 | 2024-2025 | Tlando |
| Horizon Therapeutics Plc | $36.51 | 2022 | |
| Neurocrine Biosciences, INC. | $35.14 | 2025 | |
| Pfizer INC. | $32.96 | 2022 | |
| Electromed, INC. | $24.52 | 2023 | Smartvest |
| Biotronik Nro, INC. | $23.98 | 2025 | Prospera |
| Ibsa Pharma INC. | $21.33 | 2025 | Licart, Flector, Tirosint |
| Sunovion Pharmaceuticals INC. | $19.34 | 2019 | |
| Acella Pharmaceuticals, LLC | $19.29 | 2025 | NP Thyroid 60 |
| Boston Scientific Corporation | $18.88 | 2025 | Intracept |
| Janssen Pharmaceuticals, INC | $18.57 | 2019 | |
| Hikma Pharmaceuticals USA | $18.12 | 2023 | Ryaltris |
| Bayer Healthcare Pharmaceuticals INC. | $18.10 | 2025 | |
| Currax Pharmaceuticals LLC | $15.25 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Aravind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.